Royce & Associates LP Maxcyte, Inc. Transaction History

Royce & Associates LP

$10.8 Billion
Q1 2024

A detailed history of Royce & Associates LP transactions in Maxcyte, Inc. stock. As of the latest transaction made, Royce & Associates LP holds 81,428 shares of MXCT stock, worth $319,197. This represents 0.0% of its overall portfolio holdings.

Number of Shares

81,428

Previous 327,338 75.12%

Holding current value

$319,197

Previous $1.54 Million 77.83%

% of portfolio

0.0%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$3.94 - $5.38 $968,885 - $1.32 Million	-245,910 Reduced 75.12%	81,428 $341,000
Q4 2023 Feb 12, 2024	SELL	$2.6 - $5.24 $247,577 - $498,963	-95,222 Reduced 22.53%	327,338 $1.54 Million
Q3 2023 Nov 09, 2023	BUY	$3.02 - $5.1 $71,815 - $121,277	23,780 Added 5.96%	422,560 $1.32 Million
Q2 2023 Aug 07, 2023	BUY	$3.69 - $5.35 $335,254 - $486,074	90,855 Added 29.51%	398,780 $1.83 Million
Q1 2023 May 04, 2023	BUY	$4.03 - $5.89 $152,334 - $222,642	37,800 Added 13.99%	307,925 $1.52 Million

Q4 2022 May 23, 2023	SELL	$4.92 - $7.4 $185,976 - $279,720	-37,800 Reduced 12.28%	270,125 $1.47 Million
Q4 2022 Feb 13, 2023	BUY	$4.92 - $7.4 $240,096 - $361,120	48,800 Added 22.05%	270,125 $1.48 Million
Q3 2022 Nov 03, 2022	BUY	$4.52 - $6.51 $489,628 - $705,195	108,325 Added 95.86%	221,325 $1.44 Million
Q2 2022 Aug 04, 2022	SELL	$3.59 - $6.81 $4.06 Million - $7.7 Million	-1,131,272 Reduced 90.92%	113,000 $534,000
Q1 2022 May 05, 2022	SELL	$5.26 - $10.84 $310,597 - $640,091	-59,049 Reduced 4.53%	1,244,272 $8.7 Million
Q4 2021 Feb 07, 2022	SELL	$8.87 - $12.94 $968,985 - $1.41 Million	-109,243 Reduced 7.73%	1,303,321 $13.3 Million
Q3 2021 Nov 10, 2021	BUY	$12.21 - $17.2 $17.2 Million - $24.3 Million	1,412,564 New	1,412,564 $17.2 Million

Others Institutions Holding MXCT

# of Institutions

126

Shares Held

62M

Call Options Held

2.4K

Put Options Held

2.1K

View Full List

About MAXCYTE, INC.

Ticker MXCT
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 101,724,000
Market Cap $399M
Description
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...

More about MXCT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

News

Stay updated on Royce & Associates LP with notifications on news.

Account

Royce & Associates LP Maxcyte, Inc. Transaction History